Coadministration of ezetimibe with pegylated interferon plus ribavirin could improve early virological response in chronic hepatitis C obese Egyptian patients. [electronic resource]
Producer: 20170117Description: 553-7 p. digitalISSN:- 1473-5687
- Adult
- Antiviral Agents -- adverse effects
- Drug Therapy, Combination
- Egypt
- Ezetimibe -- adverse effects
- Female
- Hepacivirus -- drug effects
- Hepatitis C, Chronic -- complications
- Humans
- Interferon-alpha -- adverse effects
- Male
- Middle Aged
- Obesity -- complications
- Polyethylene Glycols -- adverse effects
- Prospective Studies
- Recombinant Proteins -- adverse effects
- Ribavirin -- adverse effects
- Single-Blind Method
- Time Factors
- Treatment Outcome
- Viral Load
- Virus Internalization -- drug effects
No physical items for this record
Publication Type: Journal Article; Randomized Controlled Trial
There are no comments on this title.
Log in to your account to post a comment.